Zacks: AzurRx BioPharma Inc (AZRX) Given Consensus Recommendation of “Strong Buy” by Analysts

Share on StockTwits

Shares of AzurRx BioPharma Inc (NASDAQ:AZRX) have received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Analysts have set a twelve-month consensus price objective of $7.83 for the company and are predicting that the company will post ($0.24) EPS for the current quarter, according to Zacks. Zacks has also given AzurRx BioPharma an industry rank of 98 out of 255 based on the ratings given to its competitors.

Separately, HC Wainwright set a $6.00 target price on shares of AzurRx BioPharma and gave the company a “buy” rating in a research report on Monday, July 2nd.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Opaleye Management Inc. bought a new stake in AzurRx BioPharma during the second quarter worth about $417,000. Ardsley Advisory Partners lifted its position in AzurRx BioPharma by 66.3% during the second quarter. Ardsley Advisory Partners now owns 137,197 shares of the company’s stock worth $440,000 after purchasing an additional 54,697 shares during the period. Parsons Capital Management Inc. RI lifted its position in AzurRx BioPharma by 20.3% during the first quarter. Parsons Capital Management Inc. RI now owns 329,515 shares of the company’s stock worth $1,035,000 after purchasing an additional 55,540 shares during the period. 683 Capital Management LLC bought a new stake in AzurRx BioPharma during the second quarter worth about $1,284,000. Finally, Gilder Gagnon Howe & Co. LLC bought a new stake in AzurRx BioPharma during the second quarter worth about $1,782,000. 18.61% of the stock is owned by institutional investors and hedge funds.

Shares of AzurRx BioPharma stock opened at $2.49 on Tuesday. AzurRx BioPharma has a 52-week low of $2.20 and a 52-week high of $5.25.

About AzurRx BioPharma

AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.

Recommended Story: Leveraged Buyout (LBO)

Get a free copy of the Zacks research report on AzurRx BioPharma (AZRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.